Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.30 |
| ▸ | SELE | P16581 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2078311 | 0.82 | SMN1; SMN2 (0.39) | MEN1KMT2ARAB9ADYRK1A | |
| SCHEMBL20588923 | 0.79 | — | — | |
| SCHEMBL4307277 | 0.79 | — | — | |
| SCHEMBL3150437 | 0.77 | KMT2A (0.34) | MLYCDMEN1KMT2ARAB9AMAPK1 | |
| SCHEMBL28297724 | 0.76 | CNR2 (0.44) | — | |
| SCHEMBL5285523 | 0.76 | ALDH1A1 (0.47) | MLYCDMEN1KMT2ATDP1RAB9A | |
| SCHEMBL10593163 | 0.75 | — | — | |
| Trimethylammonium SCHEMBL27464061 | 0.75 | HCAR2 (0.39) | TDP1MAPK1 | |
| SCHEMBL6003817 | 0.74 | KDM4E (0.50) | MEN1KMT2ARAB9A | |
| SCHEMBL5167577 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12264138-B2 | Process for the preparation of microbiocidal oxadiazole derivatives | SYNGENTA CROP PROTECTION AG (CH) | 2025-04-01 | — | — | US | disclosed |
| US-20240174683-A1 | MAP4K1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-30 | — | — | US | disclosed |
| US-11945796-B2 | Substituted pyridine derivatives as SARM1 inhibitors | NURA BIO, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| EP-4288437-A1 | MAP4K1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2023-12-13 | — | — | EP | disclosed |
| CN-116438171-A | Substituted pyridine derivatives as SARM1 inhibitors | 努拉生物公司 | 2023-07-14 | — | — | CN | disclosed |
| WO-2022167627-A1 | MAP4K1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-08-11 | — | — | WO | disclosed |
| US-20220194907-A1 | PROCESS FOR THE PREPARATION OF MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2022-06-23 | — | — | US | disclosed |
| US-11358957-B2 | Microbiocidal oxadiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2022-06-14 | — | — | US | disclosed |
| US-20220081417-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | NURA BIO, INC. | 2022-03-17 | — | — | US | disclosed |
| US-20220081417-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | NURA BIO, INC. | 2022-03-17 | — | — | US | disclosed |
| US-20200277287-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2020-09-03 | — | — | US | disclosed |
| WO-2020068846-A1 | HETEROCYCLIC COMPOUND | HETEROCYCLIC COMPOUND (US) | 2020-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11945796-B2 | Substituted pyridine derivatives as SARM1 inhibitors | SARM1, SARNP, ADRM1 | MLYCD 2695/4885MEN1 4471/4885KMT2A 1817/4885 |
| US-20220081417-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | SARM1, SARNP, ADRM1 | MLYCD 2695/4885MEN1 4471/4885KMT2A 1817/4885 |
| US-12264138-B2 | Process for the preparation of microbiocidal oxadiazole derivatives | CYP51A1, MPO, NOX5 | MLYCD 466/4885MEN1 3852/4885KMT2A 4305/4885 |
| US-20240174683-A1 | MAP4K1 INHIBITORS | MAP3K4, MAP4K4, MAP4K1 | MLYCD 2451/4885MEN1 468/4885KMT2A 2250/4885 |
| US-20200277287-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | PRF1, NOX1, ARG2 | MLYCD 371/4885MEN1 3805/4885KMT2A 4506/4885 |
| US-11358957-B2 | Microbiocidal oxadiazole derivatives | PRF1, NOX1, ARG2 | MLYCD 371/4885MEN1 3805/4885KMT2A 4506/4885 |
| US-20220194907-A1 | PROCESS FOR THE PREPARATION OF MICROBIOCIDAL OXADIAZOLE DERIVATIVES | CYP51A1, MPO, NOX5 | MLYCD 466/4885MEN1 3852/4885KMT2A 4305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.